Janus Henderson Group PLC Has $728.44 Million Holdings in Neurocrine Biosciences, Inc. (NBIX)

Janus Henderson Group PLC cut its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 0.7% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,414,861 shares of the company’s stock after selling 49,133 shares during the quarter. Janus Henderson Group PLC owned about 8.20% of Neurocrine Biosciences worth $728,436,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Stanley Laman Group Ltd. increased its holdings in Neurocrine Biosciences by 13.6% in the 2nd quarter. Stanley Laman Group Ltd. now owns 89,884 shares of the company’s stock valued at $8,830,000 after buying an additional 10,728 shares during the period. Swiss National Bank increased its holdings in Neurocrine Biosciences by 1.8% in the 2nd quarter. Swiss National Bank now owns 156,500 shares of the company’s stock valued at $15,375,000 after buying an additional 2,800 shares during the period. American Century Companies Inc. increased its holdings in Neurocrine Biosciences by 14.0% in the 2nd quarter. American Century Companies Inc. now owns 566,895 shares of the company’s stock valued at $55,692,000 after buying an additional 69,701 shares during the period. Schwab Charles Investment Management Inc. increased its holdings in Neurocrine Biosciences by 7.5% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 472,287 shares of the company’s stock valued at $46,398,000 after buying an additional 32,769 shares during the period. Finally, CIBC World Markets Inc. bought a new stake in Neurocrine Biosciences in the 2nd quarter valued at $1,030,000.

NBIX has been the topic of several analyst reports. Robert W. Baird boosted their price target on shares of Neurocrine Biosciences from $84.00 to $100.00 and gave the company an “outperform” rating in a report on Tuesday, May 1st. JPMorgan Chase & Co. boosted their price target on shares of Neurocrine Biosciences from $100.00 to $103.00 and gave the company an “overweight” rating in a report on Tuesday, May 1st. Deutsche Bank set a $99.00 price target on shares of Neurocrine Biosciences and gave the company a “buy” rating in a report on Tuesday, May 1st. Bank of America boosted their price target on shares of Neurocrine Biosciences from $101.00 to $102.00 and gave the company a “buy” rating in a report on Tuesday, May 1st. Finally, Cowen reissued a “buy” rating and issued a $100.00 price target on shares of Neurocrine Biosciences in a report on Monday, May 7th. Seventeen analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $119.25.

NBIX opened at $118.71 on Monday. The company has a debt-to-equity ratio of 1.00, a quick ratio of 9.19 and a current ratio of 9.19. Neurocrine Biosciences, Inc. has a twelve month low of $51.42 and a twelve month high of $120.90. The stock has a market capitalization of $10.74 billion, a PE ratio of -73.28, a PEG ratio of 33.79 and a beta of 0.33.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Tuesday, July 31st. The company reported ($0.07) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.11. The business had revenue of $96.90 million for the quarter, compared to analyst estimates of $84.11 million. Neurocrine Biosciences had a negative net margin of 16.07% and a negative return on equity of 14.22%. The firm’s quarterly revenue was up 1428.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.68) EPS. analysts expect that Neurocrine Biosciences, Inc. will post 0.17 earnings per share for the current year.

In related news, insider Eric Benevich sold 12,350 shares of the company’s stock in a transaction dated Friday, June 1st. The shares were sold at an average price of $97.34, for a total transaction of $1,202,149.00. Following the transaction, the insider now owns 16,690 shares in the company, valued at approximately $1,624,604.60. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Stephen A. Sherwin sold 10,000 shares of the company’s stock in a transaction dated Monday, June 11th. The stock was sold at an average price of $98.44, for a total transaction of $984,400.00. Following the transaction, the director now owns 47,548 shares in the company, valued at approximately $4,680,625.12. The disclosure for this sale can be found here. In the last quarter, insiders have sold 170,335 shares of company stock worth $17,273,648. 4.30% of the stock is owned by corporate insiders.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.

Read More: Outstanding Shares and The Effect on Share Price

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply